Leucid Bio Announces Treatment of First Patient in AERIAL Trial of NKG2D CAR-T Therapy LEU011 for Solid Tumours
-
Initiation of AERIAL trial accelerated by successful first close of Series A1 financing
-
LEU011 is first CAR-T candidate for the treatment of solid tumours to be manufactured at Great Ormond Street Hospital (GOSH)
-
Enrolment continues in AERIAL trial with initial data for LEU011 expected in the second half of 2025
London, UK – 12 May 2025 – Leucid Bio (“Leucid” or “The Company”), a privately-held biotechnology company pursuing the development of innovative Chimeric Antigen Receptor T-cell (CAR-T) therapies using the Company’s proprietary lateral CAR platform, today announced that the first patient has been dosed in the Phase 1 AERIAL trial evaluating the safety and clinical activity of LEU011 in patients with refractory solid tumours.
